Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US House Preview: Health Panels To Push Device Tax Repeal, Shutdown Contingency Bills In 2019

Executive Summary

US House lawmakers might pursue legislation in 2019 to repeal the device tax, ensure that FDA can continue working on medtech product reviews during US government shutdowns, and to stabilize the Affordable Care Act to lower health-care costs for patients.

You may also be interested in...

Handful Of House Health Panelists Support Strong ACA And Device Tax Repeal

On the roster of the House Energy and Commerce and Ways and Means Committees in 2019 are members working toward both support of the Affordable Care Act and repeal of the device tax that helps fund it. Some on the committees, including all of the Democrats, back efforts to strengthen ACA in 2019, while many Democrats declined to repeal the device tax in a key 2018 vote. But 19 members of the panels voted to accomplish both goals.

What's Ahead In The US Senate: Support Builds For Bills To Lower Health-Care Costs, End Device Tax

The medtech industry should expect legislation to gain attention in the US Senate in the coming months to lower health-care costs and promote transparency to allow cost-conscious patients to shop for the most effective and lowest-priced surgical and advanced imaging procedures, as well as bills to repeal the device tax, key Senate health players say.

ACLA Rejects FDA As A ‘Clinical Validity’ Judge, While AdvaMedDx Seeks Tweaks To VALID Act

Clinical labs are troubled by the idea of granting US FDA vast discretion to determine if laboratory-developed tests (LDTs) are analytically and clinically valid, a key feature of the draft US VALID Act, while in vitro diagnostic kit manufacturers want some clarifications and more flexibility written into the proposal for diagnostic regulatory reforms.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts